Ongoing clinical trials are evaluating the efficacy of MET tyrosine kinase inhibitors in various solid tumor types to determine whether MET alterations can be considered a tumor-agnostic target (NCT02978261, NCT03993873, and NCT01639508). The gene discussed is MET; the disease is neoplasm.